Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base
Articolo
Data di Pubblicazione:
2023
Citazione:
Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base / F. Toto, E. Salvioni, D. Magrì, S. Sciomer, M. Piepoli, R. Badagliacca, A. Galotta, N. Baracchini, S. Paolillo, U. Corrà, R. Raimondo, R. Lagioia, P.P. Filardi, A. Iorio, M. Senni, M. Correale, M. Cicoira, E. Perna, M. Metra, M. Guazzi, G. Limongelli, G. Sinagra, G. Parati, G. Cattadori, F. Bandera, M. Bussotti, M. Mapelli, M. Cipriani, A. Bonomi, G. Cunha, F. Re, C. Vignati, A. Garascia, C. Lombardi, A.B. Scardovi, A. Passantino, M. Emdin, C. Passino, C. Santolamazza, D. Girola, D. Zaffalon, D. Vizza, F. De Martino, P. Agostoni. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 1874-1754. - 371:(2023 Jan 15), pp. 273-277. [10.1016/j.ijcard.2022.09.030]
Abstract:
Background: The prognostic role of moderate hyperkalemia in reduced ejection fraction (HFrEF) patients is still controversial. Despite this, it affects the use of renin-angiotensin-aldosterone system inhibitors (RAASi) with therapy down-titration or discontinuation. Objectives: Aim of the study was to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF optimally treated patients. Methods and results: We retrospectively analyzed MECKI (Metabolic Exercise test data combined with Cardiac and Kidney Indexes) database, with median follow-up of 4.2 [IQR 1.9-7.5] years. Data on K+ levels were available in 7087 cases. Patients with K+ plasma level >= 5.6 mEq/L and < 4 mEq/L were excluded. Remaining patients were categorized into normal >4 and < 5 mEq/L (n = 4826, 68%) and moderately high >= 5.0 and <= 5.5 mEq/L (n = 496, 7%) K+. Then patients were matched by propensity score in 484 couplets of patients. MECKI score value was 7% [IQR 3.1-14.1%] and 7.3% [IQR 3.4-15%] (p = 0.678) in patients with normal and moderately high K+ values while cardiovascular mortality events at two years follow-up were 41 (4.2%) and 33 (3.4%) (p = 0.333) in each group respectively. Conclusions: Moderate hyperkalemia does not influence patients' outcome in a large cohort of ambulatory HFrEF patients.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Heart failure; Hyperkalemia; Prognosis; Renin angiotensin aldosterone system inhibitor
Elenco autori:
F. Toto, E. Salvioni, D. Magrì, S. Sciomer, M. Piepoli, R. Badagliacca, A. Galotta, N. Baracchini, S. Paolillo, U. Corrà, R. Raimondo, R. Lagioia, P.P. Filardi, A. Iorio, M. Senni, M. Correale, M. Cicoira, E. Perna, M. Metra, M. Guazzi, G. Limongelli, G. Sinagra, G. Parati, G. Cattadori, F. Bandera, M. Bussotti, M. Mapelli, M. Cipriani, A. Bonomi, G. Cunha, F. Re, C. Vignati, A. Garascia, C. Lombardi, A.B. Scardovi, A. Passantino, M. Emdin, C. Passino, C. Santolamazza, D. Girola, D. Zaffalon, D. Vizza, F. De Martino, P. Agostoni
Link alla scheda completa: